Clinical TrialJun 4, 2026, 08:07 AM
Cognition Therapeutics Advances Zervimesine to Registrational DLB Psychosis Trial
AI Summary
Cognition Therapeutics presented an investor update highlighting the advancement of its lead asset, zervimesine (CT1812), towards a registrational trial for Dementia with Lewy bodies (DLB) psychosis. The company reported strong Phase 2 SHIMMER study results, showing an 86% slowing of NPI-12 decline in neuropsychiatric symptoms versus placebo. With $31.2 million in cash and equivalents and $25.6 million in remaining grant funds as of March 31, 2026, the company has a cash runway into Q2 2027. Additionally, the START Phase 2 trial for early Alzheimer's, fully funded by an $81 million NIA grant, is ongoing with data expected in 2H 2027.
Key Highlights
- Zervimesine (CT1812) is advancing towards a registrational program for DLB psychosis.
- SHIMMER Phase 2 study showed an 86% slowing of NPI-12 decline in neuropsychiatric symptoms vs. placebo.
- SHIMMER Phase 2 demonstrated an 89% slowing of hallucinations and delusions vs. placebo.
- FDA Division of Psychiatry meeting held May 20, 2026, to finalize registrational study design.
- Cash and equivalents totaled ~$31.2M as of March 31, 2026.
- Remaining NIA grant funds of $25.6M provide a cash runway into Q2 2027.
- START Phase 2 trial for early Alzheimer's is ongoing, funded by an $81M NIA grant.
Price Impact
More from CGTX